Study Finds Pharmacy Care Coordination Cuts Hospitalizations for Cancer Patients

Picture what it's like to start chemotherapy. You're handed a treatment plan, a stack of prescriptions, and a list of side effects to watch for, all while trying to process a life-altering diagnosis. For many patients, that's where the support ends. They're left to manage timing, dosages, and warning signs largely on their own.

New research from Humana suggests that gap in support carries real consequences, and that closing it can save both suffering and money.

The study, conducted by Humana Pharmacy Analytics and Consulting, looked at cancer patients enrolled in Humana Medicare Advantage plans with Part D prescription coverage. Researchers compared outcomes for members who received specialty pharmacy care coordination against those who opted out of it. The difference was substantial. Patients who received coordinated support saw an 11.7% reduction in hospitalizations, a 2.7% drop in emergency department visits, and a 7.7% decrease in medical costs.

Think of care coordination like having a dedicated navigator for a complicated journey. Cancer treatment involves multiple drugs, shifting schedules, and side effects that can escalate quickly if left unmonitored. A coordinator, in this case a team of pharmacists, nurses, and specialists, checks in regularly, tracks adherence, and catches problems before they become emergencies. That's the basic idea behind Humana's CenterWell Specialty Pharmacy Oncology Center of Excellence, the program at the heart of this study.

The research, published in Expert Review of Pharmacoeconomics & Outcomes Research, was retrospective and observational, meaning researchers looked backward at existing patient data rather than running a controlled experiment. That's an important caveat. Observational studies can reveal strong associations, but they can't fully rule out other factors that might explain the difference, such as patients who opt into extra support being more health-conscious to begin with. Still, the size and consistency of the results are notable.

How the Program Works

The Oncology Center of Excellence operates as an optional Part D plan benefit. Patients specifically prescribed intravenous chemotherapy, oral targeted oncolytics, or immunotherapies are eligible for this level of support. Once enrolled, they receive follow-up care, adherence support, and side effect monitoring throughout treatment, not just at the start.

That distinction matters. Cancer therapy isn't a one-time event. It's a months-long, sometimes years-long process where a missed dose or an unreported side effect can spiral into a hospital visit. Bethanie Stein, Pharm.D., president of pharmacy at Humana, framed the goal simply.

"This study shows that a differentiated, coordinated level of care is necessary to treat complex conditions like cancer," Stein said. "Our team's north star is improved health outcomes, and we designed this integrated, personalized care support approach accordingly. We surround our patients with holistic support, which helps them adhere to the treatments they're prescribed so they work as intended."

That last phrase, "work as intended," gets at something researchers and clinicians have long known but struggled to address at scale. A drug's effectiveness in a clinical trial doesn't automatically translate to effectiveness in real life. Patients skip doses because of nausea. They stop treatment early because nobody explained a manageable side effect. Coordination, at least according to this study, helps close that gap between what a medication can do and what it actually does for a given patient.

The results held steady across age groups, genders, and geographic regions. That consistency suggests the benefit isn't limited to a narrow slice of patients or a particular type of care setting. It's a broader signal about what structured support can do when layered onto complex treatment.

None of this happens in a vacuum, either. CenterWell, Humana's health services division that houses this pharmacy program alongside primary care and home health services, has become a significant growth engine for the insurer. The unit generated $12.89 billion in revenue during the first two quarters of 2026, up from $10.63 billion during the same period in 2025, according to Humana's earnings filings. The company projects CenterWell will bring in at least $25 billion in total revenue this year. In February, CenterWell expanded further by acquiring primary care provider MaxHealth from private equity firm Arsenal Capital Partners, adding dozens of clinics to its network.

That expansion context is worth sitting with. Humana isn't just publishing research, it's building a business model around integrated care delivery, one that increasingly folds pharmacy, primary care, and home health into a single platform. The financial incentives and the clinical benefits may well align here, but it's fair for patients and policymakers to keep asking whether coordinated care programs are being designed primarily around patient outcomes or around retaining members and revenue within a single corporate ecosystem. Both can be true at once, but transparency about the balance matters.

Why It Matters

For patients navigating cancer treatment, the practical takeaway is straightforward. Coordinated pharmacy support, of the kind offered through programs like the Oncology Center of Excellence, appears to reduce the chances of ending up in an emergency room or hospital bed. Fewer hospitalizations mean less physical strain, less time away from work and family, and lower costs at a moment when many patients are already facing financial pressure from treatment itself.

For the broader health system, the findings add to a growing body of evidence that medication adherence support isn't a minor add-on service. It's a meaningful lever for improving outcomes in complex, high-stakes conditions. Cancer treatment is expensive and physically taxing enough without the added burden of preventable complications from missed doses or unmonitored side effects.

The study doesn't answer every question. It can't tell us whether similar coordination models would work as well outside a Medicare Advantage population, or whether the savings would hold up under a randomized trial design. But it does offer a data point that health plans, providers, and patients alike should pay attention to: sometimes the most effective intervention isn't a new drug or a new technology. It's simply making sure someone is paying close attention to how the existing treatment is actually being used.